Astellas, Medivation announce Health Canada approval of Xtandi
The oral, once-daily androgen receptor inhibitor is indicated for treating metastatic castration-resistant prostate cancer patients, who were previously treated with docetaxel therapy, in the setting of medical or
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.